ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
StudyPopulationInverventionStudy ContactLink to study details
2
Mesenchymal Stem Cells by Mike Bowdish ON HOLDIntubated <72hr critical illnessMSC or placeboTammie Possemato
626-254-3898
tpossema@med.usc.edu
https://docs.google.com/spreadsheets/d/1dikXknJReE4xCYCElI9PIapryhdvnOzTtmFF_qptfCE/edit?usp=sharing
3
Ravulizumab by Caroline Piatek & Janice Liebler intubated COVID patients (allows patients on CPAP/BiPAP; no high flow oxygen)Ravulizumab + BSC vs BSCDonna Fernando (LAC+USC) (626) 675-7019 [cell] / (323) 409-4388 [office]
Simbiso Peresuh (Keck) (909) 726-4075 [cell] / (323) 865-3498 [office]
4
Lenzilumab by Megan Lewis & Linda Sher ON HOLDPneumonia diagnosed by chest x-ray or computed tomography (CT) revealing infiltrates consistent with pneumonia and has not yet developed ARDS at screening & Has not participated in other clinical trials for COVID-19. Note that subjects on corticosteroids, remdesivir and/or hydroxychloroquine with or without azithromycin are not excluded from the study. Level of serum ferritin ≥ 300 ng/mL at screening/baseline.IV Lenzilumab 600 mg or placebo + SOCPI Megan Lewis (Meghan.lewis@med.usc.edu/(310) 801-4070 [cell])
Christine Quesada (Christine.Quesada@med.usc.edu) and Chris Romero (Christian.Romero@med.usc.edu)
5
Convalescent Plasma by Dube, Michael Laboratory confirmed diagnosis of infection with SARS-CoV2 + Severe or life-threatening COVID-19, or judged by the treating provider to be at high-risk of progression to severe or life-threatening diseasePatients will be transfused with one unit of ABO compatible convalescent plasma obtained from individual who has recorvered from documented infection with SARS-CoV-2Dr. Dube
6
ACTIV3 by Mike Bowdish ON HOLDOngoing SARS-CoV-2 infection & Requiring admission for inpatient hospital acute medical care for clinical manifestations of COVID-19Group 1: LY3819253 + SOC (Standard of Care) Group 2: Placebo + SOC (Standard of Care)Pui Yan
(323) 422-3426
7
ISPY Trial by Julie Lang and Kashif KhanParticipants 18 years of age and older admitted to the hospital and placed on high flow oxygen (greater than 6L by nasal cannula or mask delivery system) or intubated for the treatment of (established or presumed) COVID-19.SOC + remdesivir
CCR2/5 inhibitor
Bradykinin B2 antagonist
PDE4 inhibitor
Type 1 IFN inhibitor
JAK2 inhibitor
IVIG from conv. plasma
Dr. Julie Lang (Julie.Lang@med.usc.edu, 626-240-9585)
Dr. Kashif Khan (Kashif.Khan@med.usc.edu, 323-276-4741)
8
NEPTUNE by Janice Liebler ON HOLD≥18 years old on the date of ICU admission
Systemic Inflammatory Response Syndrome (SIRS) present, as defined by the presence of two or more of the following: a. Temperature > 38°C or < 36°C b. Heart Rate > 90 beat/min c. Tachypnea > 20/min or PaCO2 < 32 mmHg d. WBC count > 12 000/mm3 or < 4 000/mm3 or > 10% immature neutrophils (bands)
Consent to study inclusion, either by patient or legal surrogate before study-related sample processing
Study sample collection within 24 hours of ICU admission order
9
AstraZeneca Vaccine Study by Dube, MichaelHigh risk participants, ≥18 years oldNon-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19Luis Mendez (lmendez@usc.edu)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100